Lipid Metabolism of Hepatocellular Carcinoma Impacts Targeted Therapy and Immunotherapy

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2023 May 1

PMID 37123054

Authors

Xiao-Chen Feng

Fu-Chen Liu

Wu-Yu Chen

Jin Du

Hui Liu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a common malignant tumor that affecting many people's lives globally. The common risk factors for HCC include being overweight and obese. The liver is the center of lipid metabolism, synthesizing most cholesterol and fatty acids. Abnormal lipid metabolism is a significant feature of metabolic reprogramming in HCC and affects the prognosis of HCC patients by regulating inflammatory responses and changing the immune microenvironment. Targeted therapy and immunotherapy are being explored as the primary treatment strategies for HCC patients with unresectable tumors. Here, we detail the specific changes of lipid metabolism in HCC and its impact on both these therapies for HCC. HCC treatment strategies aimed at targeting lipid metabolism and how to integrate them with targeted therapy or immunotherapy rationally are also presented.

Citing Articles

Chitosan capped-NLCs enhanced codelivery of gefitinib and simvastatin into MDR HCC: impact of compositions on cell death, JNK3, and Telomerase.

Harisa G, Alzhrani R, Alluhaidan A, Alamri S, Bakheit A, Asiri H Oncol Res. 2025; 33(2):477-492.

PMID: 39866231 PMC: 11754001. DOI: 10.32604/or.2024.053337.

Mitochondrial cholesterol metabolism related gene model predicts prognosis and treatment response in hepatocellular carcinoma.

Guo X, Wang F, Li X, Luo Q, Liu B, Yuan J Transl Cancer Res. 2025; 13(12):6623-6644.

PMID: 39816559 PMC: 11730194. DOI: 10.21037/tcr-24-1153.

Gene targets with therapeutic potential in hepatocellular carcinoma.

Shodry S, Hasan Y, Ahdi I, Ulhaq Z World J Gastrointest Oncol. 2024; 16(12):4543-4547.

PMID: 39678796 PMC: 11577361. DOI: 10.4251/wjgo.v16.i12.4543.

Chitosan-enclosed SLN improved SV-induced hepatocellular cell carcinoma death by modulation of IQGAP gene expression, JNK, and HDAC activities.

Harisa G, Bakheit A, Alshehri S, Attia S, Attia M Mol Biol Rep. 2024; 51(1):824.

PMID: 39023688 DOI: 10.1007/s11033-024-09757-2.

Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma.

Wang J, Liu C, Hu R, Wu L, Li C Front Pharmacol. 2024; 15:1324140.

PMID: 38362156 PMC: 10867224. DOI: 10.3389/fphar.2024.1324140.

References

McGlynn K, Petrick J, El-Serag H . Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73 Suppl 1:4-13. PMC: 7577946. DOI: 10.1002/hep.31288. View

Lin C, Gustafsson J . Targeting liver X receptors in cancer therapeutics. Nat Rev Cancer. 2015; 15(4):216-24. DOI: 10.1038/nrc3912. View

Raccosta L, Fontana R, Maggioni D, Lanterna C, Villablanca E, Paniccia A . The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J Exp Med. 2013; 210(9):1711-28. PMC: 3754872. DOI: 10.1084/jem.20130440. View

Shao W, Zhu W, Lin J, Luo M, Lin Z, Lu L . Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR. Neoplasia. 2019; 22(1):1-9. PMC: 6911865. DOI: 10.1016/j.neo.2019.08.002. View

Chan L, Ho D, Kam C, Chiu E, Lo I, Yau D . RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. J Hepatol. 2020; 74(2):360-371. DOI: 10.1016/j.jhep.2020.08.036. View

Li N, Zhou Z, Shen Y, Xu J, Miao H, Xiong Y . Inhibition of the sterol regulatory element-binding protein pathway suppresses hepatocellular carcinoma by repressing inflammation in mice. Hepatology. 2016; 65(6):1936-1947. DOI: 10.1002/hep.29018. View

Tosi M, Tugnoli V . Cholesteryl esters in malignancy. Clin Chim Acta. 2005; 359(1-2):27-45. DOI: 10.1016/j.cccn.2005.04.003. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

10.

Wei M, Nurjanah U, Herkilini A, Huang C, Li Y, Miyagishi M . Unspliced XBP1 contributes to cholesterol biosynthesis and tumorigenesis by stabilizing SREBP2 in hepatocellular carcinoma. Cell Mol Life Sci. 2022; 79(9):472. PMC: 11073046. DOI: 10.1007/s00018-022-04504-x. View

11.

Moon S, Huang C, Houlihan S, Regunath K, Freed-Pastor W, Morris 4th J . p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. 2018; 176(3):564-580.e19. PMC: 6483089. DOI: 10.1016/j.cell.2018.11.011. View

12.

Bakiri L, Hamacher R, Grana O, Guio-Carrion A, Campos-Olivas R, Martinez L . Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. J Exp Med. 2017; 214(5):1387-1409. PMC: 5413325. DOI: 10.1084/jem.20160935. View

13.

Garcia-Bermudez J, Baudrier L, Bayraktar E, Shen Y, La K, Guarecuco R . Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. Nature. 2019; 567(7746):118-122. PMC: 6405297. DOI: 10.1038/s41586-019-0945-5. View

14.

Ringel A, Drijvers J, Baker G, Catozzi A, Garcia-Canaveras J, Gassaway B . Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020; 183(7):1848-1866.e26. PMC: 8064125. DOI: 10.1016/j.cell.2020.11.009. View

15.

Mok E, Leung C, Zhou L, Lei M, Leung H, Tong M . Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma. Cancer Res. 2022; 82(17):3102-3115. DOI: 10.1158/0008-5472.CAN-21-2934. View

16.

Baek A, Yu Y, He S, Wardell S, Chang C, Kwon S . The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017; 8(1):864. PMC: 5636879. DOI: 10.1038/s41467-017-00910-z. View

17.

Mokdad A, Zhu H, Beg M, Arriaga Y, Dowell J, Singal A . Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. Target Oncol. 2019; 14(5):541-550. DOI: 10.1007/s11523-019-00663-3. View

18.

Gualdoni G, Mayer K, Goschl L, Boucheron N, Ellmeier W, Zlabinger G . The AMP analog AICAR modulates the Treg/Th17 axis through enhancement of fatty acid oxidation. FASEB J. 2016; 30(11):3800-3809. DOI: 10.1096/fj.201600522R. View

19.

Ma M, Lau E, Leung D, Lo J, Ho N, Cheng L . Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J Hepatol. 2017; 67(5):979-990. DOI: 10.1016/j.jhep.2017.06.015. View

20.

Feng T, Wu T, Zhang Y, Zhou L, Liu S, Li L . Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells. Front Oncol. 2022; 12:912694. PMC: 9361019. DOI: 10.3389/fonc.2022.912694. View